Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022

Rhea-AI Summary

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, a biopharmaceutical company, announced its participation in two investor conferences in March 2022. The company will present at the 42nd Annual Cowen Health Care Conference on March 8 at 9:50 am ET and the 34th Annual ROTH Conference from March 14-15 in Dana Point, CA. Investors can access live and archived webcasts on the Clearside website. The company focuses on innovative therapies delivered to the back of the eye via its proprietary SCS Microinjector.

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that it will participate in the following investor conferences in March 2022:

42^nd Annual Cowen Health Care Conference (Virtual)
Tuesday, March 8, 2022 at 9:50 am ET

34^th Annual ROTH Conference
Monday, March 14 – Tuesday, March 15, 2022
Dana Point, CA

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

What conferences is Clearside Biomedical attending in March 2022?

Clearside Biomedical will attend the 42nd Annual Cowen Health Care Conference on March 8 and the 34th Annual ROTH Conference from March 14-15, 2022.

When is the Cowen Health Care Conference presentation scheduled for Clearside Biomedical?

The presentation at the Cowen Health Care Conference is scheduled for March 8, 2022, at 9:50 am ET.

Where is the ROTH Conference taking place?

The ROTH Conference will take place in Dana Point, California, on March 14-15, 2022.

How can I access Clearside Biomedical's conference presentations?

You can access live and archived webcasts of Clearside Biomedical's conference presentations on their website under the Investors section.

What is the focus of Clearside Biomedical's therapies?

Clearside Biomedical focuses on delivering therapies to the back of the eye through the suprachoroidal space, aiming to improve vision in patients with sight-threatening eye diseases.